FDA Grants Breakthrough Designation to Frontline Pembrolizumab/Lenvatinib for HCC
The FDA has granted a breakthrough therapy designation to the combination of pembrolizumab and lenvatinib for the first-line treatment of patients with advanced unresectable hepatocellular carcinoma that is not amenable to locoregional therapy.
Source: OncLive